Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

被引：0
|
作者：
Rummel, Mathias J.
Buske, Christian
Hertenstein, Bernd
Lerchenmueller, Christian
Koenigsmann, Michael
Lange, Elisabeth
Reeb, Manfred
Kaiser, Ulrich
Balser, Christina
Behringer, Dirk
Durig, Jan
Gaska, Tobias
Maschmeyer, Georg
Schliesser, Georg
Burchardt, Alexander Christoph
Barth, Juergen
Kauff, Frank
Hinke, Axel
Greil, Richard
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
483
引用
收藏
页数：3
相关论文
共 49 条
  • [21] Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo
    Bastos-Oreiro, Mariana
    Gutierrez, Antonio
    Cabero Martinez, Almudena
    Lopez Jimenez, Javier
    Villafuerte Gutierrez, Paola Sandra
    Jimenez-Ubieto, Ana
    De la Fuente, Adolfo
    Navarro, Belen
    Stefania Infante, Maria
    Cordoba, Raul
    Perez De Oteyza, Jaime
    Gonzalez de Villambrosia, Sonia
    Del Campo, Raquel
    Garcia, Daniel
    Salar, Antonio
    Sancho, Juan-Manuel
    BLOOD, 2022, 140 : 3618 - 3619
  • [22] Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study
    Bastos-Oreiro, Mariana
    Gutierrez, Antonio
    Cabero, Almudena
    Lopez, Javier
    Villafuerte, Paola
    Jimenez-Ubieto, Ana
    de Ona, Raquel
    de la Fuente, Adolfo
    Navarro, Belen
    Penalver, Javier
    Martinez, Pilar
    Alonso, Carmen
    Infante, Maria
    Cordoba, Raul
    Perez-Montero, Blanca
    Perez de Oteyza, Jaime
    Gonzalez de Villambrosio, Sonia
    Fernandez-Caldas, Paula
    del Campo, Raquel
    Garcia Belmonte, Daniel
    Diaz-Galvez, Javier
    Salar, Antonio
    Sancho, Juan-Manuel
    CANCERS, 2024, 16 (07)
  • [23] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
    Margiotta-Casaluci, Gloria
    Bigliardi, Sara
    Cocito, Federica
    Meli, Erika
    Petrucci, Luigi
    Nicolosi, Maura
    Annibali, Ombretta
    Boccomini, Carola
    Bozzoli, Valentina
    Castellino, Alessia
    Cattina, Federica
    Cenfra, Natalia
    Ciavarella, Sabino
    Kovalchuk, Sofya
    Rotondo, Francesco
    Fama, Angelo
    Olivieri, Jacopo
    Zaja, Francesco
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Subanalysis of the StiL NHL 1-2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, G. -Andre
    von Gruenhagen, Ulrich
    Losem, Chrisoph
    Kofahl-Krause, Dorothea
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Weidmann, Eckhart
    Duerk, Heinz A.
    Ballo, Harald
    Stauch, Martina Beate
    Roller, Fritz
    Barth, Juergen
    Hinke, Axel
    Burchardt, Alexander C.
    Brugger, Wolfram
    BLOOD, 2012, 120 (21)
  • [25] Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance
    Morschhauser, Franck
    Nastoupil, Loretta
    Feugier, Pierre
    De Colella, Jean Marc Schiano
    Tilly, Herve
    Palomba, M. Lia
    Bachy, Emmanuel
    Fruchart, Christophe
    Libby, Edward
    Casasnovas, Rene-Olivier
    Flinn, Ian W.
    Haioun, Corinne
    Maisonneuve, Herve
    Ysebaert, Loic
    Bartlett, Nancy L.
    Bouabdallah, Kamal
    Brice, Pauline
    Ribrag, Vincent
    Le Gouill, Steven
    Daguindau, Nicolas
    Delwail, Vincent
    Pica, Gian-Matteo
    Martin Garcia-Sancho, Alejandro
    Lopez-Guillermo, Armando
    Larouche, Jean-Francois
    Ando, Kiyoshi
    Maria, Gomes da Silva
    Andre, Marc
    Wu, Ka Lung
    Sehn, Laurie H.
    Izutsu, Koji
    Cartron, Guillaume
    Gkasiamis, Argyrios
    Crowe, Russell
    Xerri, Luc
    Fowler, Nathan H.
    Salles, Gilles
    BLOOD, 2021, 138
  • [26] Interim results of a phase III study of bendamustine/rituximab versus R-CHOP as first-line therapy for patients with indolent non-Hodgkin lymphoma
    Jagannath, Sundar
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 13 - 14
  • [27] Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7-2008-MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214)
    Rummel, Mathias J.
    Lerchenmuller, Christian
    Greil, Richard
    Goerner, Martin
    Hensel, Manfred
    Engel, Erik
    Jaeger, Ulrich
    Breuer, Friedhelm
    Hertenstein, Bernd
    Prummer, Otto
    Buske, Christian
    Barth, Juergen
    Burchardt, Alexander C.
    Brugger, Wolfram
    BLOOD, 2012, 120 (21)
  • [28] BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA: EVIDENCE FROM A MULTICENTER, RETROSPECTIVE STUDY
    Mondello, P.
    Steiner, N.
    Willenbacher, W.
    Wasle, I.
    Zaja, F.
    Zambello, R.
    Visentin, A.
    Mauro, E.
    Ferrero, S.
    Ghione, P.
    Pitini, V.
    Cuzzocrea, S.
    Mian, M.
    HAEMATOLOGICA, 2016, 101 : 276 - 276
  • [29] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Wasle, Ines
    Zaja, Francesco
    Zambello, Renato
    Visentin, Andrea
    Mauro, Endri
    Ferrero, Simone
    Ghione, Paola
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1107 - 1114
  • [30] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
    Patrizia Mondello
    Normann Steiner
    Wolfgang Willenbacher
    Ines Wasle
    Francesco Zaja
    Renato Zambello
    Andrea Visentin
    Endri Mauro
    Simone Ferrero
    Paola Ghione
    Vincenzo Pitini
    Salvatore Cuzzocrea
    Michael Mian
    Annals of Hematology, 2016, 95 : 1107 - 1114
12345